| Management target | Revenue 20.0% FY27 |
|---|
| Revenue growth | Consolidated revenue up 24.3% YoY, pathology leading with 26% growth. |
|---|---|
| Margins | EBITDA margins expanded to 32.2% from improved realization and scale. |
| Demand visibility | Strong momentum in insurance and preventive segments through API integrations. |
| Management confidence | High; emphasizing structural transformation and long-term specialty shift. |
Growth
Pathology revenue grew 26% YoY, driven by a 27% surge in franchise business and improved realization per test.
Outlook
Management targets reaching 15-20% portfolio share for specialty diagnostics within 3-5 years.
Risks
High exposure to franchise churn and potential execution risks in the competitive specialty diagnostics segment.
Last quarter's promises, checked
Delivered
- Targeted 20% growth → delivered 24.3% (= BEAT)
- Guided mid-to-high teen franchise growth → delivered 27% (= BEAT)
- Guided 1,500 annual franchise additions → delivered 900 in Q1 (= BEAT)
Partly delivered
- Divest imaging business → approved but pending buyer (= PARTIAL)
Earnings Call Transcript filed with BSE, NSE: THYROCARE. Summary written with AI assistance from the document.
Thyrocare Technologies Ltd: key numbers
- Share price
- ₹515.50
- Market cap
- ₹8,205 Cr
- Revenue (annual)
- ₹829.0 Cr
- Net profit (annual)
- ₹163.0 Cr
- P/E (TTM)
- 56.9×Sector 52.3×
- Promoter holding
- 51.02%-9.90% QoQ
- FII holding
- 9.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Thyrocare Technologies Ltd
All →Thyrocare Technologies Annual General Meeting
Thyrocare Technologies reported postal ballot voting results approving the purchase of land and building from, and divestment of its entire shareholding in, Nueclear Healthcare Limited.
Thyrocare Technologies Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹270.8 Cr (+25.1%), EBITDA ₹89.3 Cr (33.0% margin), PAT before exceptions ₹60.2 Cr (+25.7%). Debt-free; NHL radiology divestment pending.
Thyrocare Technologies Results Update
Thyrocare Technologies reported Q2FY27 consolidated revenue of Rs 270.8 Cr, up 25.1% YoY, with PAT before exceptions of Rs 60.2 Cr. The press release also notes a Rs 45 Cr non-cash NHL impairment tied to a proposed divestment.
Thyrocare Technologies Q2 FY27 Results: Net Profit ₹15.2 Cr, Down 68.2% YoY
Thyrocare Technologies Ltd reported revenue from operations of ₹270.8 Cr (+25.1% YoY) and net profit of ₹15.2 Cr (-68.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹15.2 Cr · -68.2% YoY
Thyrocare Technologies Board Meeting Date
Thyrocare Technologies intimated that its Board meeting is scheduled for 29 Oct 2026 to consider Q2/H1 FY27 results. No financial figures or decisions are reported in this prior intimation.
Thyrocare Technologies Other Announcement
Thyrocare Technologies filed its quarterly shareholding pattern for the period ended September 30, 2026, including a note regarding a prior promoter group amalgamation.